Christian Herzmann
Research Subjects
Research Interests
Christian Herzmann has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
G. Janossy
HIV Clinical Research, Royal Free Hospital , London , UK
1 shared publicationH Karcher
1 shared publicationH. Wand
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales , Sydney , Australia
1 shared publicationJ Lichey
Evangelische Lungenklinik Berlin, Berlin, Germany
1 shared publicationL. Fosdick
University of Minnesota , Minneapolis, MN , USA
1 shared publicationM Johnson
The Royal Free Centre for HIV Medicine, Royal Free Hospital, London NW3 2QG, UK. E‐mail
1 shared publication
Latest Publications
- Open Access
Bronchial cast formation associated with loss of immunoglobulin and calcium
Her medication on admission included prednisolone, azathioprine, acetylcysteine and prophylactic isoniazid. There were bilateral inspiratory crackles. She required 6 l/min oxygen. Mild lung function impairment had recently been found during a less symptomatic period (forced expiratory volume in 1 s 2.13 l (74%), inspiratory vital capacity 3.02 l (88.7%), total lung capacity 4.79 l (93.9%)). Total protein (57.4 g/l), gammaglobulin (4.4 g/l) and corrected calcium (2.1 mmol/l) levels were low. The patient had selective IgG1 deficiency (IgA 0.65 g/l, IgM 1.68 g/l, IgG 4.71 g/l, IgG1 2.00 g/l, IgG2 0.91 g/l, IgG3 0.34 g/l, IgG4 0.09 g/l). No activity against granulocyte/macrophage colony-stimulating factor was found in the blood, making alveolar proteinosis unlikely. The casts consisted mainly of protein and lipids and contained significant amounts of immunoglobulins (IgG 1.63 g/l, IgA 0.33 g/l, IgM 0.45 g/l). Histological examination revealed the presence of surfactant protein A, fibrin and epithelial cells. Electron microscopy showed crystalline structures typical of calcium deposits (fig 2) and cells containing lipid particles. We were unable to quantify the calcium content. Despite our therapeutic efforts the patient’s condition is deteriorating slowly. Bronchial cast production remains and she is currently being evaluated for transplantation.
Open AccessBronchial cast formation associated with loss of immunoglobulin and calcium
Her medication on admission included prednisolone, azathioprine, acetylcysteine and prophylactic isoniazid. There were bilateral inspiratory crackles. She required 6 l/min oxygen. Mild lung function impairment had recently been found during a less symptomatic period (forced expiratory volume in 1 s 2.13 l (74%), inspiratory vital capacity 3.02 l (88.7%), total lung capacity 4.79 l (93.9%)). Total protein (57.4 g/l), gammaglobulin (4.4 g/l) and corrected calcium (2.1 mmol/l) levels were low. The patient had selective IgG1 deficiency (IgA 0.65 g/l, IgM 1.68 g/l, IgG 4.71 g/l, IgG1 2.00 g/l, IgG2 0.91 g/l, IgG3 0.34 g/l, IgG4 0.09 g/l). No activity against granulocyte/macrophage colony-stimulating factor was found in the blood, making alveolar proteinosis unlikely. The casts consisted mainly of protein and lipids and contained significant amounts of immunoglobulins (IgG 1.63 g/l, IgA 0.33 g/l, IgM 0.45 g/l). Histological examination revealed the presence of surfactant protein A, fibrin and epithelial cells. Electron microscopy showed crystalline structures typical of calcium deposits (fig 2) and cells containing lipid particles. We were unable to quantify the calcium content. Despite our therapeutic efforts the patient’s condition is deteriorating slowly. Bronchial cast production remains and she is currently being evaluated for transplantation.
- Open Access
- 10 June 2008
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 62 (3) , 583-586
Long-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients
Subcutaneous administration of interleukin-2 (IL-2) has been shown to increase CD4 counts in HIV-infected patients. It remains unclear whether this effect is associated with a clinical benefit. We conducted a long-term follow-up in the cohort of the UK-Vanguard study in which three groups of 12 antiretroviral-naive subjects with CD4 cell counts >350 cells/mm3 received no treatment or IL-2 at either 4.5 or 7.5 MIU twice daily in 5 day cycles, respectively. Mean follow-up was 376 weeks. IL-2 therapy was associated with a higher area under the curve of CD4 cell count change from baseline at week 48 but not thereafter. HIV-RNA levels were unaffected. Highly active antiretroviral therapy (HAART) was initiated after a mean of 172, 175 and 152 weeks in the control group, low-dose and high-dose IL-2 treatment group, respectively, a statistically non-significant difference. There was a tendency to start HAART soon after discontinuation of IL-2 therapy which may have been triggered by the steep decay of CD4 counts. There were two serious adverse events in the control group, seven in the low-dose IL-2 group and eight in the high-dose IL-2 group. No pattern of disease was detected, making an association with IL-2 therapy unlikely. We could detect neither a benefit of IL-2 therapy after week 48 nor delayed initiation of HAART. This is currently the longest follow-up data comparing IL-2 therapy with no therapy in antiretroviral-naive HIV-infected patients and does not show a persistent benefit of the intervention.
- 10 June 2008
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 62 (3) , 583-586
Open AccessLong-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients
Subcutaneous administration of interleukin-2 (IL-2) has been shown to increase CD4 counts in HIV-infected patients. It remains unclear whether this effect is associated with a clinical benefit. We conducted a long-term follow-up in the cohort of the UK-Vanguard study in which three groups of 12 antiretroviral-naive subjects with CD4 cell counts >350 cells/mm3 received no treatment or IL-2 at either 4.5 or 7.5 MIU twice daily in 5 day cycles, respectively. Mean follow-up was 376 weeks. IL-2 therapy was associated with a higher area under the curve of CD4 cell count change from baseline at week 48 but not thereafter. HIV-RNA levels were unaffected. Highly active antiretroviral therapy (HAART) was initiated after a mean of 172, 175 and 152 weeks in the control group, low-dose and high-dose IL-2 treatment group, respectively, a statistically non-significant difference. There was a tendency to start HAART soon after discontinuation of IL-2 therapy which may have been triggered by the steep decay of CD4 counts. There were two serious adverse events in the control group, seven in the low-dose IL-2 group and eight in the high-dose IL-2 group. No pattern of disease was detected, making an association with IL-2 therapy unlikely. We could detect neither a benefit of IL-2 therapy after week 48 nor delayed initiation of HAART. This is currently the longest follow-up data comparing IL-2 therapy with no therapy in antiretroviral-naive HIV-infected patients and does not show a persistent benefit of the intervention.
- Open Access
- 4 June 2008
- Published by Bentham Science Publishers Ltd. in The Open AIDS Journal
- Vol. 2 (1) , 39-42
Pharmacokinetics of Acetyl-L-Carnitine Given in Single or Multiple Doses to HIV-1 Infected Patients with Toxic Peripheral Polyneuropathy
The use of nucleoside reverse transcriptase inhibitors in the treatment of HIV infection is associated with antiretroviral toxic polyneuropathy (ATN). Previous studies suggest that long term treatment with Acetyl-L-carnitine (ALCAR) 1.5 gram twice daily improves symptoms and promotes nerve regeneration. It is unknown whether the drug’s pharmacokinetic profile would allow for a once daily administration. Twenty three HIV-1 infected subjects taking ALCAR for ATN were enrolled in a cross over trial and switched from twice to once daily dosing. Their regimen was changed from 1.5g twice daily to 1g (4 patients), 2g (7), and 3g (12) once daily, respectively. Twelve healthy volunteers served as control. Plasma levels of ALCAR and its metabolite L-carnitine were measured. Patients receiving ALCAR had higher pre-dose levels than control subjects. Post dose levels were not significantly higher than pre dose levels in any treatment group. The pre / post dose ALCAR concentrations were 7.6 / 7.7, 7.1 / 6.8, 7.7 / 6.8, and 7.1 / 7.5 µmol/l for 1.5g twice daily, 1g once daily, 2g once daily, and 3g once daily, respectively. All values were significantly higher than the mean concentration in the control group (4.3 µmol/l). For ALCAR and L-carnitine, measurements for once daily regimens did not differ from the twice daily regimen. Once daily dosing of ALCAR can achieve similar plasma levels as twice daily dosing but intra-mitochondrial levels remain unknown. The pharmacokinetic profile of orally administered ALCAR is complex and likely to be highly affected by endogenous concentrations.
- 4 June 2008
- Published by Bentham Science Publishers Ltd. in The Open AIDS Journal
- Vol. 2 (1) , 39-42
Open AccessPharmacokinetics of Acetyl-L-Carnitine Given in Single or Multiple Doses to HIV-1 Infected Patients with Toxic Peripheral Polyneuropathy
The use of nucleoside reverse transcriptase inhibitors in the treatment of HIV infection is associated with antiretroviral toxic polyneuropathy (ATN). Previous studies suggest that long term treatment with Acetyl-L-carnitine (ALCAR) 1.5 gram twice daily improves symptoms and promotes nerve regeneration. It is unknown whether the drug’s pharmacokinetic profile would allow for a once daily administration. Twenty three HIV-1 infected subjects taking ALCAR for ATN were enrolled in a cross over trial and switched from twice to once daily dosing. Their regimen was changed from 1.5g twice daily to 1g (4 patients), 2g (7), and 3g (12) once daily, respectively. Twelve healthy volunteers served as control. Plasma levels of ALCAR and its metabolite L-carnitine were measured. Patients receiving ALCAR had higher pre-dose levels than control subjects. Post dose levels were not significantly higher than pre dose levels in any treatment group. The pre / post dose ALCAR concentrations were 7.6 / 7.7, 7.1 / 6.8, 7.7 / 6.8, and 7.1 / 7.5 µmol/l for 1.5g twice daily, 1g once daily, 2g once daily, and 3g once daily, respectively. All values were significantly higher than the mean concentration in the control group (4.3 µmol/l). For ALCAR and L-carnitine, measurements for once daily regimens did not differ from the twice daily regimen. Once daily dosing of ALCAR can achieve similar plasma levels as twice daily dosing but intra-mitochondrial levels remain unknown. The pharmacokinetic profile of orally administered ALCAR is complex and likely to be highly affected by endogenous concentrations.
- 1 December 2005
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 6 (6) , 344-350
Long-Term Effect of Acetyl-L-Carnitine for Antiretroviral Toxic Neuropathy
Background: Nucleoside analogue reverse transcriptase inhibitors (NRTIs) used for the treatment of HIV can a cause distal symmetrical peripheral polyneuropathy by disruption of mitochondrial metabolism. Treatment with acetyl-L-carnitine (ALCAR) has shown short-term symptomatic and histological improvement. Long-term effects have not been investigated. Purpose: To assess the subjective and objective degree of antiretroviral toxic neuropathy (ATN) during treatment with ALCAR. Method: A cohort of 21 patients with ATN who commenced treatment with ALCAR between March 1999 and October 2001 was reviewed after a mean of 4.3 years using standardized questionnaires and neurological examination. Results: Of the 21 patients, 2 had died and 3 were lost to follow-up. 16 patients were assessed. 10 were still on potentially neurotoxic drugs. 13 were still taking ALCAR. 9 were pain free. The most common symptom was numbness (mild, moderate, and severe in 12, 3, and 0 patients, respectively), followed by paraesthesia (8, 2, 2), pain (4, 3, 0), and burning (5, 2, 0). There was mildly reduced sensation in the toes of 8 patients. 13 patients reported that ALCAR had improved their symptoms very much or moderately, 2 reported no change, and 1 reported a moderate worsening. Conclusion: ALCAR led to long-term symptomatic improvement in most patients without the need to discontinue neurotoxic drugs. Although in this study there was no control group, this agent appears to be an effective pathogenesis-based treatment for ATN.
- 1 December 2005
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 6 (6) , 344-350
Long-Term Effect of Acetyl-L-Carnitine for Antiretroviral Toxic Neuropathy
Background: Nucleoside analogue reverse transcriptase inhibitors (NRTIs) used for the treatment of HIV can a cause distal symmetrical peripheral polyneuropathy by disruption of mitochondrial metabolism. Treatment with acetyl-L-carnitine (ALCAR) has shown short-term symptomatic and histological improvement. Long-term effects have not been investigated. Purpose: To assess the subjective and objective degree of antiretroviral toxic neuropathy (ATN) during treatment with ALCAR. Method: A cohort of 21 patients with ATN who commenced treatment with ALCAR between March 1999 and October 2001 was reviewed after a mean of 4.3 years using standardized questionnaires and neurological examination. Results: Of the 21 patients, 2 had died and 3 were lost to follow-up. 16 patients were assessed. 10 were still on potentially neurotoxic drugs. 13 were still taking ALCAR. 9 were pain free. The most common symptom was numbness (mild, moderate, and severe in 12, 3, and 0 patients, respectively), followed by paraesthesia (8, 2, 2), pain (4, 3, 0), and burning (5, 2, 0). There was mildly reduced sensation in the toes of 8 patients. 13 patients reported that ALCAR had improved their symptoms very much or moderately, 2 reported no change, and 1 reported a moderate worsening. Conclusion: ALCAR led to long-term symptomatic improvement in most patients without the need to discontinue neurotoxic drugs. Although in this study there was no control group, this agent appears to be an effective pathogenesis-based treatment for ATN.
- Open Access
- 28 October 2005
- Published by Wiley in HIV Medicine
- Vol. 6 (6) , 379
Rash in an HIV‐positive patient
- 28 October 2005
- Published by Wiley in HIV Medicine
- Vol. 6 (6) , 379
Open AccessRash in an HIV‐positive patient
- 4 November 2004
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 351 (19) , 2013-2015
Nevirapine plus Zidovudine to Prevent Mother-to-Child Transmission of HIV
The articles by Lallemant et al. and Jourdain et al. (July 15 issue)1,2 highlight a dilemma. Should we impair the health of one patient to help another patient? Of the women receiving nevirapine, 32 percent showed resistance mutations to nonnucleoside reverse-transcriptase inhibitors (NNRTI) at 10 days post partum.2 However, viral rebound may occur 21 days3 after receipt of the drug and result in an even higher rate of resistance mutations to NNRTI. Of the mothers receiving zidovudine monotherapy, 6.3 percent transmitted the human immunodeficiency virus (HIV) to their infants, as compared with 2.8 percent of mothers treated with additional nevirapine.1 Unfortunately, no data are given on resistance mutations in infected babies. Resistance mutations might be present in 46 percent of vertically infected babies after nevirapine prophylaxis.4
- 4 November 2004
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 351 (19) , 2013-2015
Nevirapine plus Zidovudine to Prevent Mother-to-Child Transmission of HIV
The articles by Lallemant et al. and Jourdain et al. (July 15 issue)1,2 highlight a dilemma. Should we impair the health of one patient to help another patient? Of the women receiving nevirapine, 32 percent showed resistance mutations to nonnucleoside reverse-transcriptase inhibitors (NNRTI) at 10 days post partum.2 However, viral rebound may occur 21 days3 after receipt of the drug and result in an even higher rate of resistance mutations to NNRTI. Of the mothers receiving zidovudine monotherapy, 6.3 percent transmitted the human immunodeficiency virus (HIV) to their infants, as compared with 2.8 percent of mothers treated with additional nevirapine.1 Unfortunately, no data are given on resistance mutations in infected babies. Resistance mutations might be present in 46 percent of vertically infected babies after nevirapine prophylaxis.4